HomeCompareCNST vs JNJ

CNST vs JNJ: Dividend Comparison 2026

CNST yields 5.88% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNST wins by $9.5K in total portfolio value
10 years
CNST
CNST
● Live price
5.88%
Share price
$33.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.5K
Annual income
$856.30
Full CNST calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — CNST vs JNJ

📍 CNST pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNSTJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNST + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNST pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNST
Annual income on $10K today (after 15% tax)
$500.15/yr
After 10yr DRIP, annual income (after tax)
$727.85/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, CNST beats the other by $24.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNST + JNJ for your $10,000?

CNST: 50%JNJ: 50%
100% JNJ50/50100% CNST
Portfolio after 10yr
$24.8K
Annual income
$842.04/yr
Blended yield
3.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CNST
Analyst Ratings
6
Buy
6
Hold
Consensus: Buy
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNST buys
0
JNJ buys
0
No recent congressional trades found for CNST or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNSTJNJ
Forward yield5.88%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$29.5K$20.0K
Annual income after 10y$856.30$827.78
Total dividends collected$7.3K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CNST vs JNJ ($10,000, DRIP)

YearCNST PortfolioCNST Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,288$588.41$10,676$355.77+$612.00CNST
2$12,699$620.77$11,407$389.39+$1.3KCNST
3$14,241$652.67$12,198$426.53+$2.0KCNST
4$15,922$684.02$13,056$467.62+$2.9KCNST
5$17,751$714.72$13,987$513.12+$3.8KCNST
6$19,738$744.71$14,998$563.56+$4.7KCNST
7$21,894$773.91$16,098$619.52+$5.8KCNST
8$24,229$802.26$17,295$681.69+$6.9KCNST
9$26,755$829.74$18,599$750.82+$8.2KCNST
10$29,484$856.30$20,022$827.78+$9.5KCNST

CNST vs JNJ: Complete Analysis 2026

CNSTStock

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

Full CNST Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this CNST vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNST vs SCHDCNST vs JEPICNST vs OCNST vs KOCNST vs MAINCNST vs ABBVCNST vs MRKCNST vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.